Guess which ASX micro-cap stock is rocketing 80% on FDA clearance

The FDA has given the thumbs up to this company's trial plans.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chimeric Therapeutics Ltd (ASX: CHM) shares are getting a lot of attention on Tuesday.

In early trade, the ASX micro-cap was up over 80% to 4.8 cents.

The clinical stage cell therapy company's shares have eased back a touch since then but remain up 69% to 4.4 cents currently.

Why is this ASX micro-cap rocketing?

The catalyst for this strong gain has been news that the cell therapy company has received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of CHM 2101.

CHM 2101 is Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. With receipt of this clearance, the company can now begin initiating a multi-centre, open label Phase 1A/B clinical trial for patients with advanced colorectal cancer, gastric cancer, and neuroendocrine tumours.

The release notes that the clinical program for CHM 2101 builds upon the preclinical studies published in the preeminent scientific journal, Nature Cancer, in March 2022. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues.

Commenting on the trial plan, Michael R. Bishop, MD, Professor of Medicine and Director, The David and Etta Jonas Center for Cellular Therapy, University of Chicago, said:

I am really excited about the planned Phase 1 clinical trial of CHM 2101 and the opportunity to bring a potentially transformative new investigational agent to cancer patients who need them most.

Following today's gain, this ASX micro-cap now has a market capitalisation of approximately $23 million.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would ticks all of my boxes for a great investment.

Read more »

Five arrows hit the bullseye of five round targets lined up in a row, with a blue sky in the background.
Healthcare Shares

When might CSL shares hit the $300-mark again?

CSL is on track for $300, if one broker is to be believed.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

2 ASX healthcare shares I think are overdue for a big rally

I think these early stage drug companies could have a barnstorming 2024.

Read more »

Businesswoman whispering in male colleague's ear as he looks surprised
Share Gainers

Up 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?

Why are these pharmaceutical shares turning heads at the moment? The Elvest team explains.

Read more »

a woman puts a pen to her mouth as she smiles slightly while checking an old book style diary/calendar.
Healthcare Shares

Dates that could move the NIB share price in 2024

NIB shares investors, get out your 2024 diaries...

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 healthcare stock is surging 8% on record sales

This medical device company's sales growth was strong in November.

Read more »

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »